The structural role of receptor tyrosine sulfation in chemokine recognition

British Journal of Pharmacology

Volumn 171, Issue 5, 2014, Pages 1167-1179

  Ludeman, Justin P ^a   Stone, Martin J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

chemokine; chemokine receptor; structure; tyrosine sulfation

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; DIMERIZATION; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RECEPTOR BINDING; REVIEW; TYROSINE SULFATION;

CHEMOKINE; CHEMOKINE RECEPTOR; STRUCTURE; TYROSINE SULFATION;

ANIMALS; CHEMOKINES; HUMANS; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CHEMOKINE; SULFATES; TYROSINE;

EID: 84895123623     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12455     Document Type: Review

References (68)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Bielinska M, (1987). Sulfation of the choriogonadotropin alpha subunit in human placental explants. Biochem Biophys Res Commun 148: 1446-1452.
3. Bonomi M, Busnelli M, Persani L, Vassart G, Costagliola S, (2006). Structural differences in the hinge region of the glycoprotein hormone receptors: evidence from the sulfated tyrosine residues. Mol Endocrinol 20: 3351-3363.
4. Choe H, Moore MJ, Owens CM, Wright PL, Vasilieva N, Li W, et al. (2005). Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol 55: 1413-1422.
5. Colvin RA, Campanella GS, Manice LA, Luster AD, (2006). CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 26: 5838-5849.
6. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. (1997). Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16: 6996-7007.
7. Danan LM, Yu Z, Hoffhines AJ, Moore KL, Leary JA, (2008). Mass spectrometric kinetic analysis of human tyrosylprotein sulfotransferase-1 and -2. J Am Soc Mass Spectrom 19: 1459-1466.
8. Danan LM, Yu Z, Ludden PJ, Jia W, Moore KL, Leary JA, (2010). Catalytic mechanism of Golgi-resident human tyrosylprotein sulfotransferase-2: a mass spectrometry approach. J Am Soc Mass Spectrom 21: 1633-1642.
9. De Clercq E, (2010). Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 128: 509-518.
10. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, et al. (2011). Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A 108: 17655-17660.
11. Duma L, Haussinger D, Rogowski M, Lusso P, Grzesiek S, (2007). Recognition of RANTES by extracellular parts of the CCR5 receptor. J Mol Biol 365: 1063-1075.
12. Emmelkamp JM, Rockstroh JK, (2007). CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 12: 409-417.
13. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, et al. (1999). Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96: 667-676.
14. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Kuhn J, Gerard C, et al. (2001). Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor. J Exp Med 193: 1059-1066.
15. Farzan M, Babcock GJ, Vasilieva N, Wright PL, Kiprilov E, Mirzabekov T, et al. (2002a). The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry. J Biol Chem 277: 29484-29489.
16. Farzan M, Chung S, Li W, Vasilieva N, Wright PL, Schnitzler CE, et al. (2002b). Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. J Biol Chem 277: 40397-40402.
17. Fernandez EJ, Lolis E, (2002). Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42: 469-499.
18. Fieger CB, Huang MC, Van Brocklyn JR, Goetzl EJ, (2005). Type 1 sphingosine 1-phosphate G protein-coupled receptor signaling of lymphocyte functions requires sulfation of its extracellular amino-terminal tyrosines. FASEB J 19: 1926-1928.
19. Fong AM, Alam SM, Imai T, Haribabu B, Patel DD, (2002). CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J Biol Chem 277: 19418-19423.
20. Gangavarapu P, Rajagopalan L, Kolli D, Guerrero-Plata A, Garofalo RP, Rajarathnam K, (2012). The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment. J Leukoc Biol 91: 259-265.
21. Gao J, Choe H, Bota D, Wright PL, Gerard C, Gerard NP, (2003). Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin. J Biol Chem 278: 37902-37908.
22. Gao J-M, Xiang R-L, Jiang L, Li W-H, Feng Q-P, Guo Z-J, et al. (2009). Sulfated tyrosines 27 and 29 in the N-terminus of human CXCR3 participate in binding native IP-10. Acta Pharmacol Sin 30: 193-201.
23. Gutierrez J, Kremer L, Zaballos A, Goya I, Martinez AC, Marquez G, (2004). Analysis of post-translational CCR8 modifications and their influence on receptor activity. J Biol Chem 279: 14726-14733.
24. Handel TM, Domaille PJ, (1996). Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35: 6569-6584.
25. Hortin G, Sims H, Strauss AW, (1986). Identification of the site of sulfation of the fourth component of human complement. J Biol Chem 261: 1786-1793.
26. Hortin GL, (1990). Sulfation of tyrosine residues in coagulation factor V. Blood 76: 946-952.
27. Hortin GL, Farries TC, Graham JP, Atkinson JP, (1989). Sulfation of tyrosine residues increases activity of the fourth component of complement. Proc Natl Acad Sci U S A 86: 1338-1342.
28. Jen CH, Leary JA, (2010). A competitive binding study of chemokine, sulfated receptor, and glycosaminoglycan interactions by nano-electrospray ionization mass spectrometry. Anal Biochem 407: 134-140.
29. Jen CH, Moore KL, Leary JA, (2009). Pattern and temporal sequence of sulfation of CCR5 N-terminal peptides by tyrosylprotein sulfotransferase-2: an assessment of the effects of N-terminal residues. Biochemistry 48: 5332-5338.
30. Jin H, Shen X, Baggett BR, Kong X, LiWang PJ, (2007). The human CC chemokine MIP-1beta dimer is not competent to bind to the CCR5 receptor. J Biol Chem 282: 27976-27983.
31. Karp DR, (1983). Post-translational modification of the fourth component of complement. Sulfation of the alpha-chain. J Biol Chem 258: 12745-12748.
32. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I, (2007). Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: 1652-1658.
33. Komori R, Amano Y, Ogawa-Ohnishi M, Matsubayashi Y, (2009). Identification of tyrosylprotein sulfotransferase in Arabidopsis. Proc Natl Acad Sci U S A 106: 15067-15072.
34. Mayer KL, Stone MJ, (2000). NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2. Biochemistry 39: 8382-8395.
35. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, Jones DR, et al. (2001). Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 20: 2497-2507.
36. Miller LH, Mason SJ, Clyde DF, McGinniss MH, (1976). The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295: 302-304.
37. Miller LH, Baruch DI, Marsh K, Doumbo OK, (2002). The pathogenic basis of malaria. Nature 415: 673-679.
38. Mishiro E, Sakakibara Y, Liu MC, Suiko M, (2006). Differential enzymatic characteristics and tissue-specific expression of human TPST-1 and TPST-2. J Biochem 140: 731-737.
39. Moore KL, (2003). The biology and enzymology of protein tyrosine O-sulfation. J Biol Chem 278: 24243-24246.
40. Moore KL, (2009). Protein tyrosine sulfation: a critical posttranslation modification in plants and animals. Proc Natl Acad Sci U S A 106: 14741-14742.
41. Moser B, Wolf M, Walz A, Loetscher P, (2004). Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25: 75-84.
42. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM, (2009). Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol 183: 3425-3432.
43. Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M, et al. (2012). Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491: 779-783.
44. Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ, (1994). Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 33: 6952-6959.
45. Pouyani T, Seed B, (1995). PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus. Cell 83: 333-343.
46. Preobrazhensky AA, Dragan S, Kawano T, Gavrilin MA, Gulina IV, Chakravarty L, et al. (2000). Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J Immunol 165: 5295-5303.
47. Ravindran A, Sawant KV, Sarmiento J, Navarro J, Rajarathnam K, (2013). Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor. J Biol Chem 288: 12244-12252.
48. Sako D, Comess KM, Barone KM, Camphausen RT, Cumming DA, Shaw GD, (1995). A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 83: 323-331.
49. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, et al. (2012). Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165: 1617-1643.
50. Seibert C, Veldkamp CT, Peterson FC, Chait BT, Volkman BF, Sakmar TP, (2008). Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases. Biochemistry 47: 11251-11262.
51. Simpson LS, Zhu JZ, Widlanski TS, Stone MJ, (2009). Regulation of chemokine recognition by site-specific tyrosine sulfation of receptor peptides. Chem Biol 16: 153-161.
52. Stone MJ, Chuang S, Hou X, Shoham M, Zhu JZ, (2009). Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. N Biotechnol 25: 299-317.
53. Szpakowska M, Fievez V, Arumugan K, van Nuland N, Schmit JC, Chevigne A, (2012). Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. Biochem Pharmacol 84: 1366-1380.
54. Taleski D, Butler SJ, Stone MJ, Payne RJ, (2011). Divergent and site-selective solid-phase synthesis of sulfopeptides. Chem Asian J 6: 1316-1320.
55. Tan JH, Canals M, Ludeman JP, Wedderburn J, Boston C, Butler SJ, et al. (2012). Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). J Biol Chem 287: 14692-14702.
56. Tan JH, Ludeman JP, Wedderburn J, Canals M, Hall P, Butler SJ, et al. (2013). Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1). J Biol Chem 288: 10024-10034.
57. Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF, (2005). The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 14: 1071-1081.
58. Veldkamp CT, Seibert C, Peterson FC, Sakmar TP, Volkman BF, (2006). Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J Mol Biol 359: 1400-1409.
59. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC, 3rd, Basnet H, et al. (2008). Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 1: ra4.
60. Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF, (2010). Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J Am Chem Soc 132: 7242-7243.
61. Westmuckett AD, Hoffhines AJ, Borghei A, Moore KL, (2008). Early postnatal pulmonary failure and primary hypothyroidism in mice with combined TPST-1 and TPST-2 deficiency. Gen Comp Endocrinol 156: 145-153.
62. Wilkins PP, Moore KL, McEver RP, Cummings RD, (1995). Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem 270: 22677-22680.
63. Wood A, Armour D, (2005). The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 43: 239-271.
64. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
65. Ye J, Kohli LL, Stone MJ, (2000). Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. J Biol Chem 275: 27250-27257.
66. Zhu JZ, Millard CJ, Ludeman JP, Simpson LS, Clayton DJ, Payne RJ, et al. (2011). Tyrosine sulfation influences the chemokine binding selectivity of peptides derived from chemokine receptor CCR3. Biochemistry 50: 1524-1534.
67. Ziarek JJ, Heroux MS, Veldkamp CT, Peterson FC, Volkman BF, (2011). Sulfotyrosine recognition as marker for druggable sites in the extracellular space. Int J Mol Sci 12: 3740-3756.
68. Zlotnik A, Yoshie O, (2000). Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.